Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2014-12-24 Director's Dealing
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2014-12-24 English
OWNERSHIP DOCUMENT
Director's Dealing
2014-12-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2014-12-19 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content specifically reports the appointment of a new director, Kenneth Hoberman, to the Board of Directors, including his committee assignment and term details. There is no financial data or detailed report content, only an announcement of a board change. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming the classification as MANG.
2014-12-17 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text references press releases about clinical study data and includes exhibits that are press releases. The document length is 2691 characters, which is relatively short and mainly serves as an announcement of events and press releases rather than containing detailed financial data or comprehensive reports. There is no indication of annual or quarterly financial statements, audit reports, management changes, or other specific report types. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-12-09 English
Regulatory Filings 2014
Regulatory Filings
2014-11-24 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.